A biohybrid chiral hydrogel enhances preclinical postoperative glioblastoma therapy by multi-pronged inhibition of tumor stemness
RNA-seq (gene expression) · mouse · 15 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 15 samples: 5 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE308216_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1329232 and SRA study SRP620808. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 15 samples.
How we read this: 5 replicated groups read from 15 sample titles; they account for 15 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9240321 Hoechst-CD133+ GL261 cells, DGSNP + cytokine cocktail treament, Day 6, rep1 Hoechst-CD133+ GL261 ce…
- GSM9240322 Hoechst-CD133+ GL261 cells, DGSNP + cytokine cocktail treament, Day 6, rep2 Hoechst-CD133+ GL261 ce…
- GSM9240323 Hoechst-CD133+ GL261 cells, DGSNP + cytokine cocktail treament, Day 6, rep3 Hoechst-CD133+ GL261 ce…
- GSM9240324 Hoechst-CD133+ GL261 cells, DNP + cytokine cocktail treament, Day 6, rep1 Hoechst-CD133+ GL261 ce…
- GSM9240325 Hoechst-CD133+ GL261 cells, DNP + cytokine cocktail treament, Day 6, rep2 Hoechst-CD133+ GL261 ce…
- GSM9240326 Hoechst-CD133+ GL261 cells, DNP + cytokine cocktail treament, Day 6, rep3 Hoechst-CD133+ GL261 ce…
- GSM9240327 Hoechst-CD133+ GL261 cells, LGSNP + cytokine cocktail treament, Day 6, rep1 Hoechst-CD133+ GL261 ce…
- GSM9240328 Hoechst-CD133+ GL261 cells, LGSNP + cytokine cocktail treament, Day 6, rep2 Hoechst-CD133+ GL261 ce…
- GSM9240329 Hoechst-CD133+ GL261 cells, LGSNP + cytokine cocktail treament, Day 6, rep3 Hoechst-CD133+ GL261 ce…
- GSM9240330 Hoechst-CD133+ GL261 cells, PBS + cytokine cocktail treament, Day 6, rep1 Hoechst-CD133+ GL261 ce…
- GSM9240331 Hoechst-CD133+ GL261 cells, PBS + cytokine cocktail treament, Day 6, rep2 Hoechst-CD133+ GL261 ce…
- GSM9240332 Hoechst-CD133+ GL261 cells, PBS + cytokine cocktail treament, Day 6, rep3 Hoechst-CD133+ GL261 ce…
- GSM9240333 Untreated non-SP GL261 cells, Day 6, rep1 Untreated non-SP GL261 …
- GSM9240334 Untreated non-SP GL261 cells, Day 6, rep2 Untreated non-SP GL261 …
- GSM9240335 Untreated non-SP GL261 cells, Day 6, rep3 Untreated non-SP GL261 …
- GSE297312 AUTOPHAGY INHIBITION IMPROVES SENSITIVITY TO THE MULTI-KINASE INHIBITOR REGORAFENIB IN PRECLINICAL MOUSE COLON TUMOROIDS 43 samples shares preclinical, inhibition
- GSE244524 ORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome 32 samples shares preclinical, inhibition
- GSE255031 Combined inhibition of IL-1, IL-33 and IL-36 signaling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of Systemic Sclerosis 21 samples shares preclinical, inhibition
- GSE215414 Longitudinal omics data followed by preclinical treatment studies identify proteasome inhibition as potential salvage strategy for ibrutinib-resistant CLL 15 samples shares preclinical, inhibition
- GSE320177 All -trans retinoic acid suppresses CD8+ T cell terminal exhaustion which enhances anti–PD-1 efficacy against glioblastoma [RNA-Seq] 12 samples shares glioblastoma, enhances
- GSE300712 RAS(ON) multi-selective inhibition drives anti-tumor immunity in preclinical models of NRAS-mutant melanoma 12 samples shares preclinical, inhibition
- GSE316128 A preclinical candidate of cyclophilin D inhibition improves alcohol-associated liver injury 9 samples shares preclinical, inhibition
- GSE281599 Tissue-adhesive, antibacterial and antioxidant hydrogel sealant for sealing colorectal anastomotic leakage and preventing postoperative adhesion 9 samples shares postoperative, hydrogel
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.